Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma
NCT04080154
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
28
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
Anlotinib
Sponsor
Shanghai Zhongshan Hospital